drugset / Trial / NCT01980342
Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz
Phase 4
Terminated
1 enrolled
Johns Hopkins University
American College of Obstetricians and Gynecologists · collabThe Campbell Foundation · collab
NaSingle-groupOpen-labelOther
Summary
This study evaluates whether there is an interaction between etonogestrel, the progestin hormone released by the contraceptive implant Nexplanon, and efavirenz, a common medication used to treat HIV. The endpoints measured in this study will help determine if such an interaction leads to decreased contraceptive efficacy of the contraceptive implant.
Timeline
- Start
- 2014-10
- Primary completion
- 2018-04-04
- Completion
- 2018-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 400 mg | Oral |
Indications
No indication recorded.